γ-干扰素诱生蛋白10与肝病关系研究进展*

doi:10.3969/j.issn.1672-5069.2017.01.034

Abstract

Abstract: Interferon （IFN）-γ-induced protein 10 （IP-10/CXCL10） and its receptor CXCR3,appear to contribute to the pathogenesis of viral hepatitis. CXCL10 could be secreted by various cells,including T cells,NK cells,endothelial cells,hepatocytes,etc. It plays an essential role in recruiting specific T cells,NK cells and other effector cells to local inflammatory sites to control the infection by through direct or indirect interactions. IP-10 expression is also correlated with developing liver fibrosis and cirrhosis from viral hepatitis. Furthermore,high level of IP-10 in baseline has shown a clinical utility as a predictor of effective outcome of anti-viral therapy. Since the mechanism of how IP-10 modulates anti-viral responses remains unknown, further studies are still needed to investigate the interaction between IP-10 and leukocytes in the pathogenesis of hepatitis,and to evaluate whether IP-10 could be a novel therapeutic target of viral diseases.

Key words: Hepatitis B, Interferon -γ-induced protein 10, cytokines

Zhao Kai, Shang Qinghua, Song Wengang. Progress in interferon -γ-induced protein 10 in pathogenesis of liver diseases[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(1): 120-123.

References

[1] 丁红晖,郝友华,杨新星,等. HBV感染者血清趋化因子IP-10和RANTES的表达及其临床意义探讨.实用肝脏病杂志,2009,12（3）：176-178.
[2] Brownell J,Polyak SJ. Molecular pathways:hepatitis C virus,CXCL10,and the inflammatory road to liver cancer. Clin Cancer Res,2013,19（6）:1347-1352.
[3] Oo YH,Shetty S,Adams DH. The role of chemokines in the recruitment of lymphocytes to the liver. Dig Dis,2010,28（1）:31-44.
[4] Chen LJ,Lyu J,Wen XY,et al. CXC chemokine IP-10: a key actor in liver disease Hepatol Int,2013,7（3）:798-804.
[5] Chang CC,Wu CL,Su WW,et al. Interferon gamma-induced protein 10 is associated with insulin resistance and incident diabetes in patients with nonalcoholic fatty liver disease. Sci Rep,2015,5:10096.
[6] Balmasova IP,Sepiashvili RI,Malova ES,et al. Molecular biology of hepatitis B virus and immunopath ogenesis of chronic viral hepatitis B. Zh Mikrobiol Epidemiol Immunobiol,2016,32（2）:119-126.
[7] Van Raemdonck K,Van den Steen PE,Liekens S,et al. CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev,2015,26（3）:311-327.
[8] Chai Q,She R,Huang Y,et al. Expression of neuronal CXCL10 induced by rabies virus infection initiates infiltration of inflammatory cells,production of chemokines and cytokines,and enhancement of blood-brain barrier permeability. J Virol,2015, 89（1）:870-876.
[9] Martinet J,Dufeu-Duchesne T,Costa JB,et al. Altered functions of plasmacytoid dendritic cells and reduced cytolytic activity of natural killer cells in patients with chronic HBV infection. Gastroenterology,2012,143（6）:1586-1596.
[10] Liu M,Guo S,Hibbert JM,et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev,2011,22（3）:121-130.
[11] Kakimi K,Lane TE,Wieland S,et al. Blocking chemokine responsive to γ 2/interferon（IFN）-γ inducible protein and monokine induced by IFN-γ activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus specific cytotoxic T lymphocytes. J Exp Med,2001,194（12）:1755-1766.
[12] Ito H,Ando T,Ando K,et al. Induction of hepatitis B virus surface antigen-specific cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2,3-dioxygenase activity. Immunology,2014,142（4）:614-623.
[13] Xu ZH,Liu Y,Liu LM,et,al. Association of interferon-gamma induced protein 10 promoter polymorphisms with the disease progression of hepatitis B virus infection in Chinese Han population.PLoS One,2013,8（9）:e72799.
[14] Gong LL,Zhao BB,Fan WF,et al.Correlations of IFN-γ-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians.Int J Clin Exp Pathol,2015,8（7）:8367-8375.
[15] Wang J,Zhao JH,Wang PP,et al. Expression of CXC chemokine IP-10 in patients with chronic hepatitis B. Hepatobiliary Pancreat Dis Int,2008,7（1）:45-50.
[16] Mihm S,Schweyer S,Ramadori G. Expression of the chemokine IP-10 correlates with the accumulation of hepatic IFN γ and IL-18 mRNA in chronic hepatitis C but not in hepatitis B. J Med Virol,2003,70（4）:562-570.
[17] Antonelli A,Ferrari SM,Corrado A,et al. CXCR3,CXCL10 and type 1 diabetes. Cytokine Growth Factor Rev,2014,25（1）:57-65.
[18] Sayed-Ahmed L,Kotb N,El-Serogy H,et al. TNF-αand CXCL-10 correlation with insulin resistance in patients with chronic hepatitis C virus infection.Egypt J Immunol,2010,17（1）:101-111.
[19] Carlin AF,Aristizabal P,Song Q,et al.Temporal dynamics of inflammatory cytokines/chemokines during sofosbuvir and ribavirin therapy for genotype 2 and 3 hepatitis C infection. Hepatology,2015,62（4）:1047-1058.
[20] Abe T,Fukuhara T,Wen X,et al. CD44 participates in IP-10 induction in cells in which hepatitis C virus RNA is replicating,through an interaction with Toll-like receptor 2 and hyaluronan. J Virol,2012,86（11）:6159-6170.
[21] Wiegand SB,Jaroszewicz J,Potthoff A,et al. Dominance of hepatitis C virus （HCV） is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect,2015,21（7）:710.
[22] Goh CC,Roggerson KM,Lee HC,et al. Hepatitis C virus-induced myeloid-derivedsuppressor cellssuppress NK Cell IFN-γ production by altering cellular metabolism via Arginase-1. J Immunol,2016,196（5）:2283-2292.
[23] Hintermann E,Bayer M,Pfeilschifter JM,et al. CXCL10 promotes liver fibrosis by prevention of NK cell mediated hepatic stellate cell inactivation. J Autoimmun,2010,35（4）:424-435.
[24] Wang J,Wang PP,Xiang GJ,et al. Relationship between the expression of IP-10 and IP-10 mRNA in peripheral blood and HBV DNA level in patients with cirrhosis.Hepatobiliary Pancreat Dis Int,2010,9（3）:280-286.
[25] Saudy N,Shahin D,Zakaria S,et al. Serum interferon-gamma inducible protein-10:a possible player in progression of hepatitis B virus related chronic liver diseases.Int J Adv Res（Indore）,2015,3（7）:602-611.
[26] Sevgi DY,Bayraktar B,Gündüz A,et al. Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. Wien Klin Wochenschr,2016,128（1-2）:28-33.
[27] Nishikawa H,Enomoto H,Iwata Y,et al. B-cell activating factor belonging to the tumor necrosis factor family and interferon-g-inducible protein-10 in autoimmune hepatitis.Medicine （Baltimore）,2016,95（12）:e3194.
[28] Willemse SB,Jansen L,de Niet A,et al. Intrahepatic IP-10 mRNA and plasma IP-10 levels as response marker for HBeAg-positive chronic hepatitis B patients treated with peginterferon and adefovir. Antiviral Res,2016,131:148-155.
[29] Papatheodoridis G,Triantos C,Hadziyannis E,et al. Serum HBsAg kinetics and usefulness of interferon-inducible protein 10 serum in HBeAg-negative chronic hepatitis B patients treated with tenofovir disoproxil fumarate. Antivir Hepat,2015,22（12）:1079-1087.
[30] Jaroszewicz J,Ho H,Markova A,et al. Hepatitis B surface antigen（HBsAg） decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther, 2011,16（6）:915-924.
[31] Hou FQ,Wu XJ,Wang Y,et al. Rapid downregulation of programmed death-1 and interferon-c-inducible protein-10 expression is associated with favourable outcome during antiviral treatment of chronic hepatitis B.J Viral Hepat,2013,20 （1）:18-26.
[32] Sonneveld MJ,Arends P,Boonstra A,et al. Serum levels of interferon-gamma-inducible protein 10 and response to peginterferon therapy in HBeAg-positive chronic hepatitis B. J Hepatol,2013,58（5）:898-903.
[33] Chokshi S,Cooksley H,Riva H,et al. Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption.Viral Immunol,2014,27（5）:235-244.
[34] Wang Y,Zhao C,Zhang L,et al. Predictive value of interferon-gamma inducible protein 10kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients. Antiviral Res,2014,103:51-59.
[35] Chen J,Wang Y,Li J,et al. Pegylated interferon-2b up-regulates specific CD8 + T cells in patients with chronic hepatitis B. World J Gastroenterol,2010,16（48）:6145-6150.
[36] Papatheodoridis G,Goulis J,Manolakopoulos SC,et al. Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.J Hepatol, 2014,60（1）:62-68.

Progress in interferon -γ-induced protein 10 in pathogenesis of liver diseases

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[2]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[3]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[4]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[5]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[6]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[7]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[8]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[9]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[10]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[11]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[12]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[13]	Gao Wei, Hou Yong. Diagnostic efficacy of hepatic fibrosis by liver stiffness measurement in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 652-655.
[14]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[15]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.